MEA Vascular Imaging Market

Middle East & Africa Vascular Imaging Market Size & Growth (2024 to 2029)

As per the research report, the size of the Middle East and Africa Vascular Imaging market is valued at USD 0.44 billion in 2024 and is expected to reach USD 0.58 billion by 2029 at a 5.64% CAGR during the forecast period 2024 to 2029.

Main factors like the rapid increase in the geriatric population and the increasing prevalence of comorbidities such as diabetes, cancer, hypertension, osteoporosis, and pulmonary disease are anticipated to propel the prevalence rate of cardiovascular disease (CVD), which is driving the MEA vascular imaging market. Furthermore, rapid advancements in magnetic resonance imaging (MRI) techniques can help us understand various pathological conditions of atherothrombotic diseases like the associated inflammation, neovascularization, and mechanical forces related to them.

Due to the high prevalence of CVD diseases across the MEA region, market players are increasingly emphasizing developing more technologically advanced diagnostic imaging modalities to detect, diagnose and prevent cardiovascular disease at an early stage. Furthermore, the rapid advancements in non-invasive imaging technologies will play a leading role in developing appropriate therapies and prognoses, thereby reducing the overall expenses and creating value-based care for patients. All these factors support the growth of the studied market.

Adopting state-of-the-art techniques and services boosts patients' confidence in good quality healthcare. For example, Superb Microvascular Imaging (SMI) is the latest technology that detects blood vessel flow without using a contrast agent. This imaging technique has an advanced mechanism to detect blood vessel flow signals and aid in identifying and detecting even minute vascular structures, providing greater clinical precision. Such technological developments are expected to drive market revenue growth in the future.

However, the lack of qualified medical professionals, the high cost of vascular imaging instruments, the lack of reimbursement policies, and the expensive maintenance costs of imaging systems are predicted to restrain the revenue growth of the MEA vascular imaging market throughout the forecast period.

This research report on the Middle East & Africa Vascular Imaging Market has been segmented and sub-segmented into the following categories.

By Technology:

• CT
• MRI
• X-Ray
• Ultrasound
• Nuclear Imaging

By Procedure:

• Coronary Angiography
• Peripheral
• Cerebral Angiography

By Application:

• Diagnostic
• Therapeutic

By End User:

• Hospital
• Diagnostic Center

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East & Africa Vascular Imaging Market is estimated to reach a decent CAGR due to the rapid increase in the geriatric population, growing awareness of vascular imaging technologies, high healthcare spending, better healthcare insurance plans, and introduction of new vascular imaging technologies.

The UAE Vascular Imaging Market is expected to dominate the MEA vascular imaging market in the future due to the increasing number of surgeries due to CVDs, the rapid development of vascular imaging equipment for the diagnosis of various CVDs, increasing technological advancements in vascular imaging techniques, and high capital investment in the development of multi-specialty hospitals in this region.

The Saudi Arabia Vascular Imaging Market is estimated to grow at a rapid CAGR during the period owing to increasing vascular disease incidence rate, a developed healthcare sector, a large target population, supportive investments aimed to create better therapies and techniques, and a growing number of growing initiatives.

According to a recent study, the prevalence of CVD risk factors is high in the Saudi population, including two-thirds with little physical activity, half with obesity, and the half due to unhealthy diet, dyslipidemia, hypertension, and diabetes.

KEY MARKET PLAYERS

Leading companies dominating the MEA Antinuclear Antibody Test Market profiled in the report are St. Jude Medical Inc., TERUMO Corporation, Siemens Healthineers GE Healthcare, Toshiba Medical Systems Corporation, Hitachi Medical Corporation, Samsung Medison, Shimadzu Corp., Fujifilm SonoSite, Hologic Inc., Esaote SpA, Carestream Health Inc., Konica Minolta, Opinion Medical Systems, Pie Medical Imaging, CorVascular Diagnostics LLC, Evena Medical Inc., Omega Medical Imaging LLC., BK Ultrasound, and Pour imaging GmbH.,